Search Results
Venetoclax-Based Combination Therapy Chronic Lymphocytic Leukemia (CLL) - Dr. Stephan Stilgenbauer
Obinutuzumab, Ibrutinib, & Venetoclax in 17p / TP53 CLL - Dr. Stephan Stilgenbauer ASH 2022
Obinutuzumab, ibrutinib, and venetoclax in high-risk CLL: the CLL2-GIVe and CLL13 trials
Dr. Wierda on Combination Regimens With Venetoclax in CLL
Understanding ultra high-risk CLL and advances with ibrutinib therapy
Stephan Stilgenbauer
Undetectable Measurable (Minimal) Residual Disease in Chronic Lymphocytic Leukemia - ASH 2021
Dr. Davids on Cost Effectiveness of Time-Limited Therapy With Venetoclax/Obinutuzumab in CLL
Next Questions: Chronic Lymphocytic Leukemia
Veneto-STOP: MRD detection by NGS to optimize treatment outcomes with venetoclax
Can ibrutinib be used as a first-line treatment in CLL?
ASH 2019 Interview -Prof Stephan Stilgenbauer and Deborah Sims- Updates on the management of CLL/SLL
